- Letter to the Editor
- Open Access
Update of antivenom supply for redback spider bites in Japan
© Hifumi et al.; licensee BioMed Central. 2015
- Received: 30 October 2014
- Accepted: 29 December 2014
- Published: 11 February 2015
In autumn 2014, with great effort by the Ministry of Health, Labour and Welfare, the research group will obtain several vials of redback spider (RBS) antivenom for emergency use. However, these small amounts of antivenom are insufficient to cover the demands from majority of hospitals in Japan. The research group carefully discussed the domestic RBS antivenom production by themselves for this emergency. We have now entered the second stage for large-scale antivenom production. Although the domestic production of RBS antivenom has started, great caution is required as we move forward with this plan.
- Redback spiders
- Domestic production
Letter to the editor
We previously reported that symptoms of redback spider (RBS) bites are usually mild and localized, such as local pain and erythema . However, fatal cases had been reported before the development of antivenom, which is manufactured by the immunization of horses [2,3].
RBSs were found in Metropolitan Tokyo on September 25, 2014, and they are rapidly becoming a nationwide problem in Japan . The definitive treatment for RBS envenomation is to use the specific RBS antivenom produced by the Commonwealth Serum Laboratories (CSL) in Australia. However, a serious issue with the current practice is that RBS antivenom is used as an off-label drug in Japan and must be privately imported from Australia .
To compound this issue, RBS antivenom imports from CSL were suspended in autumn 2013. The Ministry of Health, Labour and Welfare (MHLW) launched a research group to evaluate the safety and efficacy of the antivenom and to organize and maintain information on RBS bites from April 2013 . In autumn 2014, with great effort by MHLW, the research group will obtain several vials of antivenom for emergency use. However, these small amounts of antivenom are insufficient to cover the demands from majority of hospitals in Japan.
The research group carefully discussed the option for domestic RBS antivenom production by themselves for this emergency. The first stage started in April 2014. Over 5,000 RBSs were collected, and their venom was extracted by research group in the summer of 2014. We have now entered the second stage of development to evaluate the potency for large-scale antivenom production.
We foresee many difficulties in this process. First, because supplemental details of current RBS antivenom production were not obtained, we have had to refer to a method described over 60 years ago . Second, not many horses were immunized due to the limited grant fund, raising the possibility that we will be unable to obtain enough antivenom, especially if the horses die. Third, because this is the first time we have attempted to produce RBS antivenom, unexpected problems may occur.
In conclusion, although the domestic production of RBS antivenom has started, great caution is required as we move forward with this plan.
This study was supported by the Health Science Grants (2013–2015) from the Ministry of Health, Labour and Welfare of Japan.
- Hifumi T, Fujimi S, Yamagishi T, Arai S, Sawabe K, Yamamoto A, et al. Clinical characteristics of redback spider bites. J Intensive Care. 2014;2:ᅟ.Google Scholar
- Sutherland SK. Australian animal toxins. Melbourne: Oxford University Press; 1983.Google Scholar
- Braitberg G, Segal L. Spider bites—assessment and management. Aust Fam Physician. 2009;38:862–7.PubMedGoogle Scholar
- Japan ‘not ready’ for invasion of redbacks as venomous Australian spiders reach Tokyo [http://www.abc.net.au/news/2014-10-20/redback-spiders-found-for-the-first-time-in-tokyo/5827612]
- Wiener S. The Australian red back spider (Latrodectus hasseltii). II. Effect of temperature on the toxicity of venom. Med J Aust. 1956;43:331–4.PubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.